Charles Schwab’s Avadel Pharmaceuticals AVDL Stock Holding History

Charles Schwab’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-793,752	Closed	-$17.1M	–	3463
2025 Q4	$17.1M	Sell	793,752 -5,731	-0.7%	-$111K	﹤0.01%	1849
2025 Q3	$12.2M	Buy	799,483 +13,037	+2%	+$170K	﹤0.01%	2017
2025 Q2	$6.96M	Buy	786,446 +560,007	+247%	+$4.92M	﹤0.01%	2182
2025 Q1	$1.77M	Buy	226,439 +3,641	+2%	+$30.5K	﹤0.01%	2651
2024 Q4	$2.34M	Buy	222,798 +2,434	+1%	+$29.6K	﹤0.01%	2626
2024 Q3	$2.89M	Sell	220,364 -337	-0.2%	-$5.13K	﹤0.01%	2596
2024 Q2	$3.1M	Buy	+220,701	New	+$3.6M	﹤0.01%	2550

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Charles Schwab's AVDL Position: Q1 2026 in Review

Charles Schwab sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 793,752 shares — an estimated $17.1M sold.

Charles Schwab first reported a position in AVDL in Q2 2024 and held it in 7 quarters. The position peaked at $17.1M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Charles Schwab reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Charles Schwab sold 793,752 Avadel Pharmaceuticals shares in Q1 2026, an estimated $17.1M.
Charles Schwab first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 7 quarters.
Charles Schwab's Avadel Pharmaceuticals position peaked at $17.1M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.